Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. REPL
stocks logo

REPL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
--
--
-0.823
+4.19%
--
--
-0.840
+2.46%
--
--
-0.650
-31.58%
Estimates Revision
The market is revising Downward the revenue expectations for Replimune Group, Inc. (REPL) for FY2026, with the revenue forecasts being adjusted by -72.17% over the past three months. During the same period, the stock price has changed by 66.35%.
Revenue Estimates for FY2026
Revise Downward
down Image
-72.17%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+0.35%
In Past 3 Month
Stock Price
Go Up
up Image
+66.35%
In Past 3 Month
Wall Street analysts forecast REPL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is 11.43 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast REPL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is 11.43 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 10.530
sliders
Low
3.00
Averages
11.43
High
18.00
Current: 10.530
sliders
Low
3.00
Averages
11.43
High
18.00
BMO Capital
Evan Seigerman
Underperform
to
Market Perform
upgrade
$2 -> $11
2025-11-03
Reason
BMO Capital
Evan Seigerman
Price Target
$2 -> $11
2025-11-03
upgrade
Underperform
to
Market Perform
Reason
BMO Capital analyst Evan Seigerman upgraded Replimune to Market Perform from Underperform with a price target of $11, up from $2. The firm says current share levels "reflect appropriate risk" for the company's RP1 program. Replimune seems to have better alignment with regulators on a path forward for the drug, the analyst tells investors in a research note. BMO says Replimune's "productive" Type A meeting supports potential approval.
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$12
2025-10-27
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$12
2025-10-27
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Replimune to Buy from Neutral with a $12 price target after the company resubmitted the biologics license application for RP1 plus Opdivo for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The firm increased its probability of approval of RP1 plus Opdivo in anti-PD1 failed melanoma patients to 85% from 50%. The FDA indicated that this resubmission is considered a comprehensive response to the complete response letter received in July, the analyst tells investors in a research note.
Wedbush
Neutral -> Outperform
upgrade
$4 -> $18
2025-10-20
Reason
Wedbush
Price Target
$4 -> $18
2025-10-20
upgrade
Neutral -> Outperform
Reason
Wedbush upgraded Replimune to Outperform from Neutral with a price target of $18, up from $4.
Wedbush
Neutral -> Outperform
upgrade
$4 -> $18
2025-10-20
Reason
Wedbush
Price Target
$4 -> $18
2025-10-20
upgrade
Neutral -> Outperform
Reason
As previously reported, Wedbush upgraded Replimune to Outperform from Neutral with a price target of $18, up from $4. The firm notes the company announced FDA acceptance of BLA submission for RP1 plus nivolumab in advanced melanoma, with a PDUFA date for April 10, 2026, based on an FDA Class II resubmission timeline. The submission is considered to be a complete response to the CRL that Replimune received in July this year. Wedbush views the FDA turnaround following a Type A meeting with Replimune as highly promising. The firm says it has to assume that the FDA has given somewhat of a green light for the re-submission, which includes additional information.
Leerink
Market Perform -> Outperform
upgrade
2025-10-20
Reason
Leerink
Price Target
2025-10-20
upgrade
Market Perform -> Outperform
Reason
Leerink upgraded Replimune to Outperform from Market Perform.
Leerink
Jonathan Chang
Market Perform
to
Outperform
upgrade
$3 -> $13
2025-10-20
Reason
Leerink
Jonathan Chang
Price Target
$3 -> $13
2025-10-20
upgrade
Market Perform
to
Outperform
Reason
Leerink analyst Jonathan Chang upgraded Replimune to Outperform from Market Perform with a price target of $13, up from $3, after FDA accepted the application resubmission of RP1 plus nivolumab in anti-PD-1 failed melanoma with an action date of April 10, 2026. Following the news and a talk with management, Leerink has renewed confidence in RP1. It sees potential approval of RP1 and nivolumab by the action date and first patient dosing in the RP2 plus durvalumab biliary tract cancer maintenance cohort in the second half of 2025 as potential catalyst for the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Replimune Group Inc (REPL.O) is -3.70, compared to its 5-year average forward P/E of -7.23. For a more detailed relative valuation and DCF analysis to assess Replimune Group Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.23
Current PE
-3.70
Overvalued PE
-1.66
Undervalued PE
-12.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.95
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.66
Undervalued EV/EBITDA
-7.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.56
Current PS
0.00
Overvalued PS
32.84
Undervalued PS
-17.72
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

REPL News & Events

Events Timeline

(ET)
2025-11-06
08:06:01
Replimune announces Q2 earnings per share of 90 cents, surpassing consensus estimate of 79 cents.
select
2025-10-20 (ET)
2025-10-20
07:03:51
Replimune reveals FDA has accepted BLA resubmission for RP1
select
2025-10-19 (ET)
2025-10-19
17:09:35
Replimune reveals additional ad hoc analysis from the IGNYTE phase 2 cohort of RP1
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-27Benzinga
The Short List: Current Top 10 Most Shorted Stocks

  • Reasons for Short Selling: Traders short stocks to either bet on a decline in value or to profit from potential short squeezes, where rising prices force short sellers to buy back shares, creating a feedback loop of increasing demand.

  • Characteristics of Heavily Shorted Stocks: Stocks become heavily shorted when experienced traders believe they are overvalued, indicating serious risks, while retail traders may see high short interest as an opportunity for quick gains.

  • Top Heavily Shorted Stocks: As of November 26, 2025, the most shorted stocks include The Wendy's Co. (WEN) at 55.36% short interest, followed by Cambium Networks Corp. (CMBM) and Lucid Group, Inc. (LCID).

  • Risks and Volatility: While short squeezes can lead to significant gains, they come with high risks and volatility, necessitating careful monitoring and due diligence by traders.

[object Object]
Preview
6.5
11-17WSJ
Opinion | Advances in Technology Are Turning the Tide in the Fight Against Cancer

  • James Watson's Legacy: James Watson, the co-discoverer of DNA's double-helix structure, passed away at the age of 97, having expressed a desire to see a cure for cancer during his lifetime.

  • Advancements in Cancer Treatment: Significant progress has been made in cancer treatment, with previously terminal cancers now being curable, thanks to more targeted and precise therapies compared to traditional chemotherapy and radiation.

[object Object]
Preview
9.0
11-07WSJ
Editorial | The FDA's Crisis Intensifies

  • FDA's Performance: The FDA is currently in the news for negative reasons, indicating a failure in its responsibilities that could have serious implications for patient health.

  • UniQure's Gene Therapy: Biotech firm UniQure has reported that the FDA has altered the criteria for approving its gene therapy for Huntington’s disease, a condition with no current approved treatments to slow its progression.

  • Breakthrough Therapy Designation: The FDA had previously designated UniQure’s treatment as a “breakthrough therapy” in April, highlighting its potential significance in addressing a critical health issue.

  • Impact on Patients: The ongoing dysfunction within the FDA raises concerns about the timely approval of therapies that could benefit patients suffering from debilitating diseases like Huntington’s.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Replimune Group Inc (REPL) stock price today?

The current price of REPL is 10.53 USD — it has increased 2.03 % in the last trading day.

arrow icon

What is Replimune Group Inc (REPL)'s business?

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

arrow icon

What is the price predicton of REPL Stock?

Wall Street analysts forecast REPL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is 11.43 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Replimune Group Inc (REPL)'s revenue for the last quarter?

Replimune Group Inc revenue for the last quarter amounts to -84.29M USD, increased 43.07 % YoY.

arrow icon

What is Replimune Group Inc (REPL)'s earnings per share (EPS) for the last quarter?

Replimune Group Inc. EPS for the last quarter amounts to -82555000.00 USD, increased 102.72 % YoY.

arrow icon

What changes have occurred in the market's expectations for Replimune Group Inc (REPL)'s fundamentals?

The market is revising Downward the revenue expectations for Replimune Group, Inc. (REPL) for FY2026, with the revenue forecasts being adjusted by -72.17% over the past three months. During the same period, the stock price has changed by 66.35%.
arrow icon

How many employees does Replimune Group Inc (REPL). have?

Replimune Group Inc (REPL) has 479 emplpoyees as of December 05 2025.

arrow icon

What is Replimune Group Inc (REPL) market cap?

Today REPL has the market capitalization of 826.01M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free